international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including
some customer ending the distribution contract with some retailer which resulted in reduced sales volume since Q4/2017. Meanwhile there was some customer changing the sales format from export to domestic
and installation of the pipeline 239.05 248.60 (3.84) Income from water production and distribution 31.25 24.31 28.55 Income from installation and distribution of water production systems 3.40 25.03
) (70.9 %) 2.7 % Gross Margin 364.5 28.0 % 374.4 29.1 % (2.6 %) Distribution Costs (197.2) (15.1 %) (148.8) (11.6 %) 32.5 % Administrative Expenses (63.2) (4.9 %) (57.9) (4.5 %) 9.0 % Profit before Income
40 11 28% 30 50 -20 -40% Distribution costs -90 -70 -20 29% -62 -59 -3 5% Administrative expenses -108 -181 73 -40% -75 -150 75 -50% Finance cost - Interest expenses -11 -11 - - -8 -7 -1 14% Corporate
) (73.0 %) (1,030.4) (70.8 %) (10.1 %) Gross Margin 341.7 27.0 % 424.0 29.2 % (19.4 %) Distribution Costs (196.1) (15.5 %) (182.5) (12.5 %) 7.4 % Administrative Expenses (72.5) (5.7 %) (91.6) (6.3 %) (20.9
products increased 16.2%. Revenues from rendering of services decreased 63.91% due to less margins from publishing, distribution and other service from foreign publications. Thus, the company will no